The Met receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) play an important role in mediating both tumor progression and tissue regeneration. The N-terminal and first Kringle domains (NK1) of HGF comprise a naturally occurring splice variant that retains the ability to activate the Met receptor. However, NK1 is a weak agonist and is relatively unstable, limiting its therapeutic potential. Here, we engineered NK1 mutants with improved biochemical and biophysical properties that function as Met receptor agonists or antagonists. We first engineered NK1 for increased stability and recombinant expression yield using directed evolution. The NK1 variants isolated from our library screens acted as weak Met receptor antagonists due to a mutation at the NK1 homodimerization interface. We introduced point mutations that restored this NK1 homodimerization interface to create an agonistic ligand, or that further disrupted this interface to create more effective antagonists. The rationally engineered antagonists exhibited melting temperatures up to approximately 64°C, a 15°C improvement over antagonists derived from wild-type NK1, and approximately 40-fold improvement in expression yield. Next, we created disulfide-linked NK1 homodimers through introduction of an N-terminal cysteine residue. These covalent dimers exhibited nearly an order of magnitude improved agonistic activity compared to wild-type NK1, approaching the activity of full-length HGF. Moreover, covalent NK1 dimers formed from agonistic or antagonistic monomeric subunits elicited similar activity, further signifying that NK1 dimerization mediates agonistic activity. These engineered NK1 proteins are promising candidates for therapeutic development and will be useful tools for further exploring determinants of Met receptor activation.
The Met receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) play an important role in mediating both tumor progression and tissue regeneration. The N-terminal and first Kringle domains (NK1) of HGF comprise a naturally occurring splice variant that retains the ability to activate the Met receptor. However, NK1 is a weak agonist and is relatively unstable, limiting its therapeutic potential. Here, we engineered NK1 mutants with improved biochemical and biophysical properties that function as Met receptor agonists or antagonists. We first engineered NK1 for increased stability and recombinant expression yield using directed evolution. The NK1 variants isolated from our library screens acted as weak Met receptor antagonists due to a mutation at the NK1 homodimerization interface. We introduced point mutations that restored this NK1 homodimerization interface to create an agonistic ligand, or that further disrupted this interface to create more effective antagonists. The rationally engineered antagonists exhibited melting temperatures up to approximately 64°C, a 15°C improvement over antagonists derived from wild-type NK1, and approximately 40-fold improvement in expression yield. Next, we created disulfide-linked NK1 homodimers through introduction of an N-terminal cysteine residue. These covalent dimers exhibited nearly an order of magnitude improved agonistic activity compared to wild-type NK1, approaching the activity of full-length HGF. Moreover, covalent NK1 dimers formed from agonistic or antagonistic monomeric subunits elicited similar activity, further signifying that NK1 dimerization mediates agonistic activity. These engineered NK1 proteins are promising candidates for therapeutic development and will be useful tools for further exploring determinants of Met receptor activation.
T he Met receptor is a transmembrane receptor tyrosine kinase that plays a critical role in embryonic development and organ formation (1) (2) (3) . Activation of Met by its ligand, hepatocyte growth factor (HGF), supports tissue regeneration and induces a range of cellular responses including cell motility, mitosis, angiogenesis, and tubule morphogenesis (4) . Thus, there is great interest in developing Met receptor agonists to support wound healing and tissue repair. In contrast, dysregulation of Met receptor signaling widely occurs in solid tumors, resulting in a phenotype of invasion and metastasis that correlates with poor clinical prognosis (4, 5) . Met receptor antagonists are currently in various stages of clinical trials for cancer therapy (5) , although no agents are yet approved by the US Food and Drug Administration.
Native protein ligands are promising starting points for developing receptor agonists or antagonists (6) . HGF is an approximately 80 kDa multidomain protein composed of an N-terminal hairpin domain, four Kringle domains, and a C-terminal serine protease homology domain ( Fig. S1A) (7) . Although HGF is thought to bind to the Met receptor Sema domain (8-10), a critical role for the immunoglobulin-like (IPT) domains of Met has also been reported (11) . HGF is secreted as an inactive single-chain protein that must be activated through proteolytic cleavage into a disulfide-linked α∕β heterodimer. Point mutations that disrupt the proteolytic processing of HGF (12) or the conformational maturation following cleavage (13) transform full-length HGF from a Met agonist into an antagonist. By contrast, a synthetic HGF fragment comprising the N-terminal domain and all four Kringle domains (NK4) functions as a Met antagonist without further modification (14) .
The NK1 fragment of HGF (comprising the N-terminal and first Kringle domains) is a naturally occurring HGF splice variant that retains binding to Met, but elicits much weaker Met receptor activation compared to full-length HGF. NK1 binding to Met is enhanced by heparan-sulfate proteoglycans (HSPGs) (15) . Met receptor dimerization and activation is mediated through a heparin-induced NK1 homodimer (16, 17) , and these molecular events appear to underlie the mechanism of HGF-Met activation (8, 18) . The NK1 fragment can be transformed from a weak agonist into an antagonist through point mutations targeted to its homodimerization interface (19) . NK2, another naturally occurring HGF splice variant, comprises the N-terminal and first two Kringle domains of HGF. NK2 can be transformed from an antagonist to an agonist by disrupting the NK1-K2 intraprotomer interaction and then can be turned back into an antagonist by introducing the same point mutations that block NK1 homodimerization (20) .
The HGF variants described above have provided important insights into HGF-Met structure and function; however, they generally suffer from low recombinant expression yield or stability, limiting their practical use and study. For example, although NK1 is one of the smallest HGF fragments, we found that it possesses relatively low stability, and previous reports have noted difficulty with expression (19, 21) . Here, we used directed evolution to engineer NK1 mutants with substantial improvements in stability and recombinant expression yield compared to wild-type NK1. Next, we used the mechanistic basis of NK1-Met activation to rationally introduce point mutations into these NK1 mutants to generate agonistic or antagonistic variants. In addition, we created covalent NK1 homodimers that exhibited remarkable improvements in agonistic activity compared to wild-type NK1, with activity levels approaching that of full-length HGF.
Results

NK1
Engineering. HGF exists as two different isoforms, isoform 1 (I1) and isoform 3 (I3), that are identical in sequence, except for a five amino acid deletion in the first Kringle domain (K1) of I3 compared to I1. We expressed NK1 fragments corresponding to I1 or I3 on the yeast cell surface as genetic fusions to the agglutinin mating protein Aga2p (Fig. S1 B and C) . NK1 I1 was expressed on the yeast cell surface, but exhibited only weak levels of binding to soluble, recombinant Met extracellular domain (Met-Fc) (Fig. S1D) . Similar results were obtained in the presence of heparin (Fig. S1D) , which has been shown to enhance the affinity of the NK1-Met interaction (15) . Binding levels were indistinguishable for 20 or 200 nM Alexa-488 labeled Met-Fc (Met-Fc A488) and remained unchanged after heating to 70°C (Fig. S1E) , suggesting that the low levels of binding observed was nonspecific. Similar behavior was observed for NK1 I3.
We performed two rounds of directed evolution to identify NK1 mutants with improvements in stability and Met binding affinity as outlined in Fig. 1 . Using error-prone PCR, we created a first-generation mutant library (M1) of approximately 3 × 10 7 yeast transformants. The library contained a relatively equal mixture of mutants based on NK1 I1 or NK1 I3, as confirmed by DNA sequencing. To facilitate folding of NK1 mutants, we conducted two rounds of library screening after inducing for yeast cell surface expression at 20°C. High-throughput FACS was used to isolate functional NK1 mutants that bound to Met-Fc A488 (Fig. 1B) . Subsequent library sorts were conducted in parallel, using either 20 or 30°C expression temperatures ( Fig. 1 C and  D) , with the goal of screening for NK1 mutants with improved stability using the higher temperature. After six or seven rounds of library sorting (seven rounds with 20°C expression temperature, or two rounds with 20°C followed by four rounds with 30°C expression temperature) the library was enriched with mutants that bound to soluble Met-Fc A488.
The pools of mutants from the final sort rounds above were randomly mutated by error-prone PCR to generate a secondgeneration mutant library (M2) of approximately 8 × 10 7 yeast transformants. The first two rounds of sorting of this library were conducted using a 20°C expression temperature to recover mutants that bound to soluble Met-Fc A488 (Fig. 1E) . For subsequent sort rounds, we screened in parallel for NK1 mutants with increased Met binding affinity using decreasing concentrations of soluble Met-Fc A488 (Fig. 1 F and G) , or for NK1 mutants with increased stability using expression at elevated temperatures (37°C) ( Fig. 1 H and I) . Ultimately, we obtained a pool of NK1 mutants that had been screened for improvements in Met binding affinity, and a second pool that had been screened for improved stability while retaining Met binding capability.
Sequences of NK1 Mutants. Following the second round of directed evolution, we sequenced eight randomly selected clones from each of the final two sort rounds from the affinity-and stability-sorted pools. All 32 clones analyzed contained the NK1 I1 sequence and none were based on NK1 I3; thus, in subsequent studies we used wild-type and mutant NK1 proteins based on NK1 I1. Interestingly, there was substantial overlap in mutations identified from the affinity-and stability-sorted library pools, with eight mutations present in over half of the individual NK1 mutants. These eight dominant mutations are distributed across the NK1 surface as shown in Fig. 2 . None of the individual mutants contained all eight of the most common mutations; however, one variant from the affinity-sorted pool, referred to as M2.1, contained five of the eight most frequent mutations and no additional mutations (K62E, N127D, K137R, K170E, and N193D). We added the remaining three mutations (Q95R, K132N, and Q173R) to this variant to generate the NK1 mutant we term M2.2 ( Table 1) .
Binding of NK1 Proteins to Cellular Met Receptor. NK1 binds both to Met and heparin/HSPGs, which are widely coexpressed on the mammalian cell surface. NK1 mutations located in the proximity of the heparin binding sites (K62E, Q95R, K132N, and K170E) still allowed for strong, albeit decreased, heparin binding compared to wild-type NK1 (Fig. S2A ). Therefore, we used two independent approaches to measure NK1 binding to cellular Met receptor, taking care to avoid the complicating factors of NK1 binding to HSPGs. In one approach, we used BaF3 cells, a murine pre-B cell line that is devoid of HSPG expression (15) , that have been stably transfected with Met (termed BaF3-Met cells) (22) . Wild-type NK1 and the mutant M2.2 bound to BaF3-Met cells, but not to untransfected BaF3 cells (Fig. S3A ). Binding was inhibited by preincubation with the neutralizing Met antibody AF276 (R&D Systems), demonstrating Met receptor binding specificity (Fig. S3B) . In a second approach, we blocked HSPGs on the surface of A549 human lung carcinoma cells by preincubation with basic fibroblast growth factor (bFGF, also known as FGF-2), which binds to HSPGs. Following preincubation with bFGF, no decrease in binding was observed with AF276, whereas M2.2 binding was diminished, demonstrating binding of M2.2 to HSPGs on the mammalian cell surface (Fig. S3C ). M2.2 binding was completely inhibited by preincubation with both bFGF and AF276, demonstrating specificity to HSPGs and Met (Fig. S3D) .
Using these assays, M2.2 exhibited similar binding affinities to both BaF3-Met cells and A549 cells, with equilibrium binding constant (K D ) values of 22 AE 5 nM and 30 AE 10 nM, respectively ( Fig. S4 A and B) . Wild-type NK1 bound to Met expressed on BaF3-Met cells with a K D of 16 AE 4 nM (Fig. S4A) , however, bound nonspecifically to A549 cells even in the presence of bFGF. M2.1 exhibited minimal binding to Met in both assays, which was unexpected given that M2.1 was isolated from the affinity-sorted pool of NK1 mutants in the second round of directed evolution. In contrast, both wild-type NK1 and M2.2 bound to Met with affinities in the low nanomolar range.
NK1 Mutants Exhibit Enhanced Stability over Wild-Type NK1. To retain its structural integrity, we found that wild-type NK1 must be maintained in buffer containing high salt concentrations (>200-300 mM NaCl). As further evidence of this requirement, wild-type NK1 exhibited a broad, delayed elution profile on size-exclusion chromatography with buffer containing moderate salt concentration (137 mM NaCl) (Fig. 3A, Inset) , suggesting unfolding and/or nonspecific binding to the column under these conditions. In contrast, M2.1 and M2.2 eluted as a single, sharp peak on size-exclusion chromatography under similar moderate salt conditions (Fig. 3A) .
We tested the thermal stability of the NK1 proteins using two independent approaches. In the first approach, binding measurements of yeast-displayed M2.1 or M2.2 to Met-Fc A488 after heating to various temperatures resulted in T m values of 61 AE 1°C and 61.4 AE 0.7°C, respectively (Fig. S5A) . It was not possible to monitor stability of yeast-displayed wild-type NK1 in this manner because it was not functionally expressed on the yeast cell surface (Fig. S1 D and E) . In the second approach, we used CD scans to monitor secondary structure unfolding as a function of temperature. CD spectra of soluble, recombinant M2.1 and M2.2 were indistinguishable from wild-type NK1 (Fig. S5B) and were in good agreement with previous reports for wild-type NK1 (23) . A spectra of wild-type NK1 at 80°C resembled that of denatured protein (Fig. S5B) (24) , demonstrating the ability to discriminate folded and unfolded NK1 proteins using CD. Wild-type and mutant NK1 proteins each unfolded irreversibly
¼ 63.9 AE 0.5°C and 69 AE 1°C, respectively) compared to wild-type NK1 (T m ¼ 50.7 AE 0.2°C) (Fig. 3B) . These results were confirmed by monitoring the unfolding of M2.1 near the local maximum at 236 nm, which was in agreement with the T m value measured at 208 nm (approximately 65°C and 64°C, respectively).
Point Mutations at the NK1 Homodimerization Interface. Residue N127 lies within the linker region connecting the N and K1 domains (Fig. 2) . The side chain of this asparagine residue forms two hydrogen bonds central to the NK1 homodimer, and these stabilizing interactions are important to the agonistic activity of NK1 (17, 19 ). In our library-isolated variants, we observed frequent mutation of this asparagine to aspartate (N127D) ( Table 1) . To probe the effects of the N127D mutation on biological activity, we generated a series of point mutants at this position. An alanine residue was previously shown to transform wild-type NK1 from an agonist into an antagonist by disrupting stabilizing interactions of the NK1 homodimer (19) . We also explored the effects of mutation to lysine and arginine at this position, which introduce steric and electrostatic obstructions through bulky, charged side chains. In addition, we generated the point mutant D127N, which reverts this position back to the wild-type asparagine residue. Within the context of M2.2, which contains the N127D mutation, we refer to these mutations as D127A, D127K, D127R, and D127N. Importantly, each of these mutants retained the high thermal stability associated with M2.2 (Table S1 ). In general, we observed a correlation between thermal stability, as measured by CD, and yeast surface expression levels (Fig. 3C) or percent yeast surface expression (Fig. 3D) . A similar relationship was observed for yeast surface expression properties and recombinant expression yield (Fig. S5 C and D) . 
Blank spaces indicate same residue as huHGF. HGF Isoform 1 numbering scheme is used. *Linker region connecting N and K1 domains of NK1. contains the N127D mutation, exhibited weak (Fig. S6A) or no agonistic activity (Fig. 4A and Fig. S6B ). In contrast, reversion of position 127 to the wild-type asparagine residue (M2.2 D127N) resulted in agonistic activity in both MDCK scatter (Fig. 4A and Fig. S6A ) and uPA assays (Fig. S6B) . The activity of M2.2 D127N was similar to that of wild-type NK1, and both showed enhanced activity in the presence of soluble heparin (Fig. S6C) . In comparison, M2.2 D127A, D127K, and D127R did not exhibit agonistic activity in these assays either in the presence or absence of heparin ( Fig. 4A and Fig. S6 A-C) .
We next tested the ability of these mutants to inhibit HGF-induced Met activation. M2.2 D127N did not inhibit HGF-induced activity, providing further evidence of its function as a Met receptor agonist (Fig. 4B and Fig. S7 ). M2.2 mutants D127A, D127K, and D127R exhibited weak or minimal inhibition of HGF-induced MDCK cell scatter in the absence of soluble heparin (Fig. S7, Top) . In contrast, strong antagonistic activity was observed with the addition of 2 μM heparin (Fig. S7, Bottom) , likely due to a role of heparin in enhancing the NK1-Met binding interaction. Preformulating the NK1 mutants with a 2∶1 molar ratio of heparin:NK1 was sufficient to confer this antagonistic activity (Fig. 4B) . Unmodified M2.2 (M2.2 N127D) exhibited only weak antagonistic activity with a 2∶1 molar ratio of heparin (Fig. 4B) , supporting the utility of the rationally engineered point mutations. The antagonistic activity of M2.2 D127K is similar to that of the previously reported antagonist NK1 N127A (Fig. 4B) . However, the M2.2 D127 A/K/and R mutants possess markedly improved stability and expression compared to NK1 N127A, namely lower salt-dependent stability, an increased T m of approximately 15°C, and approximately 40-fold improved recombinant expression yield, which are all attractive properties for therapeutic development.
Covalent M2.2 D127N and M2.2 D127K Homodimers Exhibit Potent
Agonistic Activity. We generated NK1 homodimers by coupling monomers through a direct disulfide bond. We hypothesized that such covalent homodimers would elicit enhanced agonistic activity compared to wild-type NK1, which relies on noncovalent heparininduced dimerization for receptor activation (15, 19) . Based on the proximity of the N termini of the two protomers in the NK1 homodimer (Fig. S8A) , a free cysteine residue was introduced at the N terminus of M2.2 D127N. Interestingly, spontaneous formation of disulfide-linked dimers was observed upon recombinant expression in yeast (Fig. S8B) . These cystine-linked M2.2 D127N dimers (termed cdD127N) were purified from monomeric species by sizeexclusion chromatography and used directly in biological assays. We also generated a cystine-linked M2.2 D127K dimer (termed cdD127K) to test the biological activity of covalent homodimers based on an antagonistic monomeric subunit. The cdD127N and cdD127K proteins migrated as monomers when analyzed by reducing SDS-PAGE (Fig. S8C) , confirming that dimers are formed through a direct disulfide bond. Remarkably, both cdD127N and cdD127K induced MDCK cell scatter at an order of magnitude lower concentration than the M2.2 D127N monomer (Fig. 5A and Fig. S8D ), which shows comparable agonistic activity to wildtype NK1 (Fig. S6C) . The cystine-linked dimers also elicited similar increases in uPA activation compared to the M2.2 D127N monomer ( Fig. 5 B and C) .
Discussion
Here, we used a combination of approaches to develop therapeutic protein ligands with improved biochemical and biophysical properties. Directed evolution of NK1 identified mutations that conferred improved stability and recombinant expression yield while maintaining receptor binding affinity, and subsequent rational engineering studies generated Met receptor agonists or antagonists.
Receptor Binding Affinity. We developed two strategies to measure binding of NK1 to cellular Met receptor, taking care to avoid complicating factors of contributions by HSPGs. We found the binding affinity of wild-type NK1 to cellular Met receptor to be in the low nanomolar range (16 AE 4 nM) . Heparin has been reported to enhance NK1-Met binding affinity (15, 19, 20) , but here we report reasonably strong NK1-Met binding in the absence of heparin. This affinity is considerably stronger than previous measurements that used recombinant forms of the Met extracellular domain (20, 25) , suggesting that Met may adopt different conformations when expressed on the mammalian cell surface. It is also possible that the instability of wild-type NK1 has made accurate determination of its Met binding affinity challenging. Interestingly, wild-type NK1 reached a higher maximum binding plateau than M2.2 (Fig. S4A) . This could be due to differences in kinetic dissociation rate constants, perhaps with M2.2 unbinding more quickly during the secondary antibody incubation and wash steps. Alternatively, an intriguing possibility is that Met receptor binding may induce homodimerization of NK1, but not M2.2, resulting in an increased binding signal for wild-type NK1 due to higher binding stoichiometry. This also would suggest that both Met binding and heparin binding are involved in promoting NK1 homodimerization.
Surprisingly, the NK1 mutants we identified did not exhibit increased affinity over wild-type NK1. The low starting stability of wild-type NK1 likely resulted in a requirement for substantial stability evolution, and thus subsequent screens for improved affinity may have served only to restore the native affinity of wild-type NK1. For example, M2.1 and M2.2 exhibited somewhat similar stabilities (T m ¼ 64°C and 69°C, respectively), but M2.2 had substantially higher Met binding affinity than M2.1 (Fig. S4) . Nevertheless, these mutants provide a good starting point for further affinity maturation studies, and the approaches outlined here can be used to monitor Met receptor interactions in their native cellular context.
Stability Engineering and Relationship to Soluble Expression Yield.
Though wild-type NK1 exhibited a T m of approximately 51°C, we had difficulties with its expression, purification, and storage, and substantial troubleshooting and optimization were required in order to obtain functional protein. As an example, functional production and purification of wild-type NK1 required buffers to be autoclaved to prevent protein degradation. In addition, wildtype NK1 required high salt concentrations (>200-300 mM NaCl) to prevent destabilization and denaturation. By comparison, NK1 mutants M2.1 and M2.2 were considerably less sensitive to buffer conditions and retained their activity in buffers with lower salt concentrations.
The enhanced stability of M2.1 was surprising given that it was isolated from the affinity-sorted pool of mutants. Because wildtype NK1 is not functionally expressed on the yeast cell surface, it is possible that simply evolving for functional expression resulted in enhanced protein stability. Comparison of wild-type NK1 and each of the engineered NK1 mutants revealed a correlation between yeast surface expression levels and thermal stability (Fig. 3C) . The proteins were partitioned into populations of low stability/low yeast surface expression (comprising wild-type NK1 and NK1 N127A) or high stability/high yeast surface expression (comprising the stability-enhanced NK1 mutants) (Fig. 3C) . In yeast cell surface display, an intrinsic negative yeast population is always present that does not express protein ( Fig. 1 and Fig. S1D) ; this is generally attributed to plasmid loss (26) , but a role for protein stability has also been speculated (27) . In support of the latter, we observed a similar correlation between thermal stability and the percentage of yeast that express protein on their surface, with the strongest trends observed for expression at 30 and 37°C (Fig. 3D) . Additionally, similar trends were observed between recombinant yield and yeast surface expression levels (Fig. S5C) or percent yeast surface expression (Fig. S5D) . Taken together, these results demonstrate the power of yeast induction temperature to impart library screening stringency on thermal stability and recombinant yield in directed evolution studies. Consequently, the engineered NK1 mutant M2.2 was produced at substantially higher yield than wild-type NK1 (30 mg∕L for M2.2, compared to 3.5 mg∕L for NK1). These results are in general agreement with previous studies that report a strong correlation between yeast surface expression levels and soluble secretion efficiency (28, 29) or between yeast surface expression level and thermal stability (30) for proteins with immunoglobulin folds.
Receptor Activation and Mechanistic Insights. Interestingly, 7 out of the 11 commonly occurring NK1 mutations were changed to the corresponding residues in the HGF family member macrophage stimulating protein (MSP), HGF orthologs, or other Kringle domains (Table S2 ). Such mutations are often found in improved variants isolated from combinatorial libraries (31) and implies that for a given tertiary structure nature selects particular residues for protein folding, expression, and stability. Residues K62, K132, and K170 are located at the heparin binding sites within NK1. The mutation to the opposite charge (K62E, K170E) or a neutrally charged residue (K132N) within mutant M2.2 may improve stability by alleviating some of the energetic penalty associated with clustering positive charges to form the heparin binding site (Fig. S2 B-E) . The Q173R mutation occurs at a position previously reported to be important for interaction with Met (32), and K137R lies at the N-K1 intradomain interface and may potentially form a cross-domain interaction that stabilizes NK1 conformational flexibility.
Restoration of the native NK1 homodimerization interface in the stability-enhanced mutant M2.2 D127N results in essentially identical agonistic activity to wild-type NK1, and disruption of this interface by the M2.2 D127A/K/and R mutants results in efficient receptor antagonism, further supporting the physiologic relevance of NK1-NK1 crystallographic interface (17, 19, 20) . The improved NK1 mutants described here could support further development of other Met agonists that are comprised partially or wholly from the unstable wild-type NK1 fragment (33) (34) (35) , and given their enhanced stability have potential to be readily incorporated into biomaterials for therapeutic applications (36) . In addition, these engineered NK1 agonists and antagonists will be important tools for further elucidating determinants of Met binding and activation. As previous studies point to the biological relevance of the NK1-NK1 dimerization interface (8, 18, 19) , information into NK1 structure and function will provide direct insights into the mechanism of full-length HGF-Met activation. Interestingly, even though the individual M2.2 D127K monomeric subunits have antagonistic activity, cdD127K is a potent agonist with similar activity to cdD127N, highlighting the importance of a NK1 homodimer in mediating activation. Moreover, the ability to transform the antagonistic M2.2 D127K monomer into an agonist by covalent cross-linking implies a receptor clustering mechanism rather than requirement for a specific homodimeric conformation. The potent agonistic activity attained with these covalent NK1 dimers opens up a myriad of applications in regenerative medicine where the instability and poor expression yield of recombinant HGF have been a severe limitation.
In summary, we used a combination of rational and combinatorial engineering methods to develop receptor agonists and antagonists with therapeutic potential. Because ligandreceptor interactions are important regulators of signaling pathways involved in health and disease, similar protein engineering strategies have great promise for application to other therapeutically relevant systems.
Methods
Additional information is provided in SI Materials and Methods.
Library Generation. NK1 I1 consists of amino acids Tyr28 to Glu210 of HGF isoform 1 (Genbank Accession ID NP_000592), and NK1 I3 consists of amino acids Tyr28 to Glu205 of HGF isoform 3 (Genbank Accession ID NP_001010932).
DNA encoding the open reading frame of NK1 I1 or NK1 I3 was cloned into the pTMY-HA yeast display plasmid using NheI and MluI restriction sites. The M1 library was generated by error-prone PCR and homologous recombination as previously described (26) using primers with 50 bp of sequence homology to pTMY-HA and equal amounts of NK1 I1 and NK1 I3 plasmid DNA template. Briefly, a range of mutation frequencies were obtained using low-fidelity Taq polymerase (Invitrogen) and varying amounts of the nucleotide analogs 8-oxo-dGTP and dPTP (TriLink Biotech) (37) in separate PCR reactions consisting of five cycles (200 μM analogs), 10 cycles (2 μM or 20 μM analogs), or 20 cycles (2 μM analogs). PCR products were amplified in the absence of analogs and a total of 80 μg of mutated cDNA insert and 8 μg restriction-digested pTMY-HA backbone was transformed into EBY100 yeast by electroporation (38) . A library of approximately 3 × 10 7 transformants was obtained, as estimated by plating serial dilutions and colony counting. Sequence analysis of randomly selected clones revealed an equal distribution based on NK1 I1 and I3 templates, a mutation rate of 0.2-4.7% for individual mutants, and an average mutation rate of 1.3% for 6,400 sequenced base pairs. The M2 library was created by error-prone PCR using 100 ng DNA from the products of M1 Sort 6 30°C and M1 Sort 7 20°C. Additional mutations were randomly introduced using nucleotide analogs as described above. A total of 75 μg of mutated cDNA insert and 7.5 μg restriction-digested pTMY-HA backbone was electroporated into EBY100 yeast to generate a library of approximately 8 × 10 7 transformants.
Library Screening. Met-Fc protein was conjugated to Alexa 488 (Met-Fc A488) according to the manufacturer's instructions except the labeling time was shortened to 10 min to minimize the dye∶protein conjugation ratio. Various concentrations of Met-Fc A488 were incubated with yeast-displayed libraries in 1× PBS pH 7.4 containing 1 mg∕mL bovine serum albumin (PBS/BSA) for 3 h at room temperature. For the final hour, the anti-HA antibody 6E2 (Cell Signaling Technology) was added at a final dilution of 1∶20. Cells were pelleted by centrifugation, washed with 1 mL ice-cold PBS/BSA, and resuspended in PBS/BSA containing a 1∶20 dilution of R-Phycoerythrin conjugated goat anti-mouse secondary antibody (Sigma P9670) for 25 min on ice. Cells were washed as above and sorted using a Vantage SE flow cytometer (Stanford FACS Core Facility) and CellQuest software (Becton Dickinson Biosciences). Collected yeast cells were amplified in SD-CAA pH 4.5 media and induced for expression in SG-CAA media at 20, 30, or 37°C, as appropriate, and additional rounds of FACS were used to obtain enriched pools of mutants. The first round of FACS for M1 and M2 libraries consisted of three separate sorts totaling approximately 1 × 10 8 sorted cells, whereas subsequent sort rounds analyzed at least 10× the number of yeast collected in the previous round to ensure sufficient sampling of remaining library diversity. Sort stringency was increased by decreasing the concentration of Met-Fc A488 (for affinity screening) or increasing induction temperature to 37°C (for stability screening). Plasmid DNA was recovered from yeast cultures using a Zymoprep kit (Zymo Research) and transformed into XL-1 blue supercompetent Escherichia coli cells (Stratagene) for plasmid miniprep. DNA sequencing was performed by Elim Biopharmaceuticals.
